Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases

Journal of Gastroenterology

Volumn 48, Issue 2, 2013, Pages 177-181

  Grover, Madhusudan ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

Buspirone; Citalopram; Norepinephrine; Paroxetine; Receptor; Reuptake; Serotonin; SLC6A4; Tricyclic antidepressants; Venlafaxine

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; PAROXETINE; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; SEROTONIN RECEPTOR AFFECTING AGENT;

DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFECT; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR FUNCTION; SEROTONINERGIC SYSTEM; STOMACH EMPTYING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; PATHOPHYSIOLOGY;

DYSPEPSIA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; SEROTONIN AGENTS;

MLCS; MLOWN;

EID: 84880975421     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0726-5     Document Type: Review

References (42)

1. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274: 1527-31.
2. Camilleri M, Busciglio I, Carlson P, McKinzie S, Burton D, Baxter K, Ryks M, Zinsmeister AR. Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol. 2008;295:G219-25.
3. Fukudo S, Kanazawa M, Mizuno T, Hamaguchi T, Kano M, Watanabe S, et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage. 2009;47: 946-51.
4. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology. 2006;130: 1466-79.
5. van Oudenhove L, Kindt S, Vos R, Coulie B, Tack J. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther. 2008;28: 1326-33.
6. Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut. 1994;35: 496-500.
7. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8: 159-66.
8. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol. 2003;284: G130-7.
9. Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, et al. SPECT imaging of the stomach: comparison with barostat and effects of sex, age, body mass index, and fundoplication. Gut. 2002;51: 781-6.
10. Breen M, Camilleri M, Burton D, Zinsmeister AR. Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. Neurogastroenterol Motil. 2011;23: 308-15.
11. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10: 1239-45.
12. van Kerkhoven LA, Laheij RJ, Aparicio N, De Boer WA, Van den Hazel S, Tan AC, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo- controlled trial. Clin Gastroenterol Hepatol. 2008;6: 746-52.
13. Bouras EP, Talley NJ, Camilleri M, Burton DD, Heckman MG, Crook JE, et al. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2008;103: 2043-50.
14. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34: 638-48.
15. Talley NJ, Locke GR 3rd, Herrick LM, Silvernail VM, Prather CM, Lacy BE, et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials. 2012;33: 523-33.
16. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther. 2005;21(Suppl 2): 42-6.
17. Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137: 1261-9.
18. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders.Gastroenterology. 2006;130: 1480-91.
19. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367: 1626-35.
20. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed.... Neurogastroenterol Motil. 2005;17: 311-6.
21. Chial HJ, Camilleri M, Ferber I, Delgado-Aros S, Burton D, McKinzie S, et al. Effects of venlafaxine, buspirone and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol. 2003;1: 211-8.
22. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1: 219-28.
23. Tack J, Broekaert D, Corsetti M, Fischler B, Janssens J. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther. 2006;23: 265-74.
24. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55: 1095-103.
25. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53: 108-15.
26. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B, North of England IBS Research Group. Gastroenterology. 2003;124: 303-17.
27. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99: 914-20.
28. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipationpredominant irritable bowel syndrome: a double-blind randomized- controlled study. Aliment Pharmacol Ther. 2005;22: 381-5.
29. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48: 252-63.
30. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidencebased systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;10:S1-35.
31. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009;302: 2361-2.
32. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308: 1246-53.
33. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58: 367-78.
34. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15: 1548-53.
35. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;8:CD003460.
36. Vahedi H, Merat S, Momtahen S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27: 678-84.
37. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50: 78-86.
38. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58: 367-78.
39. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32: 1221-33.
40. Masand PS, Gupta S, Schwartz TL, Kaplan D, Virk S, Hameed A, et al. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics. 2002; 43: 451-5.
41. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32: 1221-33.
42. Drossman, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125: 19-31.